Ask AI
ProCE Banner Activity

Integrating Novel Mechanisms in Relapsed/Refractory Multiple Myeloma

Video

This program will explore the role of novel mechanisms of action in later-line therapy, with particular emphasis on the clinical profile and practical integration of selinexor-based regimens. The discussion will review key clinical trial data supporting selinexor in combination strategies and consider how these findings inform sequencing decisions in an increasingly complex therapeutic environment.

In addition to pivotal data, the program will address real-world considerations such as patient selection, tolerability management, dose optimization strategies, and positioning relative to other available classes.

Released: April 23, 2026